Suppr超能文献

在肾癌中对肾脏药物转运体活性的体外特征分析。

In Vitro Characterization of Renal Drug Transporter Activity in Kidney Cancer.

机构信息

Department of Urology, University Medicine Greifswald, 17475 Greifswald, Germany.

出版信息

Int J Mol Sci. 2022 Sep 5;23(17):10177. doi: 10.3390/ijms231710177.

Abstract

The activity of drug transporters is central to the secretory function of the kidneys and a defining feature of renal proximal tubule epithelial cells (RPTECs). The expression, regulation, and function of these membrane-bound proteins is well understood under normal renal physiological conditions. However, the impact of drug transporters on the pathophysiology of kidney cancer is still elusive. In the present study, we employed different renal cell carcinoma (RCC) cell lines and a prototypical non-malignant RPTEC cell line to characterize the activity, expression, and potential regulatory mechanisms of relevant renal drug transporters in RCC in vitro. An analysis of the uptake and efflux activity, the expression of drug transporters, and the evaluation of cisplatin cytotoxicity under the effects of methylation or epidermal growth factor receptor (EGFR) inhibition showed that the RCC cells retained substantial drug transport activity. In RCC cells, P-glycoprotein was localized in the nucleus and its pharmacological inhibition enhanced cisplatin toxicity in non-malignant RPTECs. On the other hand, methylation inhibition enhanced cisplatin toxicity by upregulating the organic cation uptake activity in RCC cells. Differential effects of methylation and EGFR were observed in transporter expression, showing regulatory heterogeneity in these cells. Interestingly, the non-malignant RPTEC cell line that was used lacked the machinery responsible for organic cation transport, which reiterates the functional losses that renal cells undergo in vitro.

摘要

药物转运体的活性是肾脏分泌功能的核心,也是肾近端小管上皮细胞(RPTEC)的一个重要特征。在正常的肾脏生理条件下,这些膜结合蛋白的表达、调节和功能已经得到了很好的理解。然而,药物转运体对肾癌病理生理学的影响仍然难以捉摸。在本研究中,我们使用不同的肾细胞癌(RCC)细胞系和一个典型的非恶性 RPTEC 细胞系,在体外研究了 RCC 中相关肾药物转运体的活性、表达和潜在的调节机制。对摄取和外排活性、药物转运体的表达以及顺铂细胞毒性在甲基化或表皮生长因子受体(EGFR)抑制作用下的评估表明,RCC 细胞保留了大量的药物转运活性。在 RCC 细胞中,P-糖蛋白定位于细胞核,其药理学抑制作用增强了非恶性 RPTEC 中的顺铂毒性。另一方面,甲基化抑制通过上调 RCC 细胞中的有机阳离子摄取活性增强了顺铂的毒性。在转运体表达方面观察到甲基化和 EGFR 的差异效应,表明这些细胞存在调节异质性。有趣的是,所使用的非恶性 RPTEC 细胞系缺乏负责有机阳离子转运的机制,这再次强调了体外培养的肾细胞发生的功能丧失。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5ed6/9456511/9c5e808f59e2/ijms-23-10177-g0A1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验